Literature DB >> 1918998

Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease.

M A Lampe1, R Patarca, M V Iregui, H Cantor.   

Abstract

Studies of systemic autoimmune disease have led to the view that initiation and progression of the disease process reflects chronic and sustained B cell activation by unidentified polyclonal activating agents. In earlier studies, we found that T cells from MRL/1 mice, which develop murine lupus, express very high levels of a newly defined T cell cytokine, Eta-1. Inasmuch as chronic and sustained B cell stimulation by T cells is a cardinal feature of MRL/1 disease, we determined the effects of this cytokine on Ig production by B cells. We show that both recombinant and biochemically purified natural Eta-1 stimulate IgM and IgG production by mixtures of B cells and macrophages from the autoimmune MRL/l strain. Additional studies suggest that optimal Ig production by Eta-1 may require macrophages and reflect enhanced Ig production by large B cells. These findings support the view that elevated levels of endogenous Eta-1 may cause chronic and sustained polyclonal B cell activation that leads to autoimmune disease in this murine model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

Review 2.  Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.

Authors:  T L Rothstein; B Guo
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

3.  Molecular characterization and expression analysis of osteopontin cDNA from lactating mammary gland in yak (Bos grunniens).

Authors:  W L Bai; R J Yang; R H Yin; W Q Jiang; G B Luo; R L Yin; S J Zhao; C Li; Z H Zhao
Journal:  Mol Biol Rep       Date:  2011-07-01       Impact factor: 2.316

Review 4.  Delayed expression of osteopontin after focal stroke in the rat.

Authors:  X Wang; C Louden; T L Yue; J A Ellison; F C Barone; H A Solleveld; G Z Feuerstein
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 5.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

6.  B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways.

Authors:  Benchang Guo; Joseph R Tumang; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

7.  Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.

Authors:  C M Giachelli; N Bae; M Almeida; D T Denhardt; C E Alpers; S M Schwartz
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 8.  Abnormalities in the regulation of variable region genes that encode for antibodies to DNA may be a central factor in the pathogenesis of systemic lupus erythematosus.

Authors:  A K Singh
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

Review 9.  Genetic associations in type I interferon related pathways with autoimmunity.

Authors:  Angélica M Delgado-Vega; Marta E Alarcón-Riquelme; Sergey V Kozyrev
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

10.  Association of the osteopontin rs1126616 polymorphism and a higher serum osteopontin level with lupus nephritis.

Authors:  Saeedeh Salimi; Mehrangiz Noora; Sima Nabizadeh; Mahnaz Rezaei; Hossain Shahraki; Mohammadoo-Khorassani Milad; Anoosh Naghavi; Farzaneh Farajian-Mashhadi; Zahra Zakeri; Mahnaz Sandoughi
Journal:  Biomed Rep       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.